Breadcrumb

[A17-02] Reslizumab (severe eosinophilic asthma) – Benefit assessment according to § 35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2017-01-16 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 196 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A17-22] Reslizumab (asthma) - Addendum to Commission A17-02
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2017-04-18 Extract of dossier assessment 196 kBPDFdownload file
2017-04-18 Dossier assessment (German version) 363 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance


Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close